SCR&TOX
Stem Cells for Relevant Efficient Extended and Normalized Toxicology
| Coordinatore | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
| Nazionalità Coordinatore | France [FR] |
| Totale costo | 9˙400˙000 € |
| EC contributo | 4˙700˙000 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2010-Alternative-Testing |
| Funding Scheme | CP-IP |
| Anno di inizio | 2011 |
| Periodo (anno-mese-giorno) | 2011-01-01 - 2015-12-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | coordinator | 1˙062˙606.80 |
| 2 |
TAKARA BIO EUROPE AB
Organization address
address: ARVID WALLGRENS BACKE 20 contact info |
SE (GOETEBORG) | participant | 612˙269.00 |
| 3 |
UNIVERSITAETSKLINIKUM BONN
Organization address
address: Sigmund-Freud-Strasse 25 contact info |
DE (BONN) | participant | 399˙218.00 |
| 4 |
JRC -JOINT RESEARCH CENTRE- EUROPEAN COMMISSION
Organization address
address: Rue de la Loi 200 contact info |
BE (BRUSSELS) | participant | 313˙426.66 |
| 5 |
UNIVERSITAET LEIPZIG
Organization address
address: RITTERSTRASSE 26 contact info |
DE (LEIPZIG) | participant | 293˙322.88 |
| 6 |
KAROLINSKA INSTITUTET
Organization address
address: Nobels Vag 5 contact info |
SE (STOCKHOLM) | participant | 267˙996.97 |
| 7 |
CXR BIOSCIENCES LIMITED
Organization address
address: James Lindsay Place 2 contact info |
UK (Dundee) | participant | 237˙205.77 |
| 8 |
CIT SAS
Organization address
address: MISEREY contact info |
FR (EVREUX) | participant | 236˙858.94 |
| 9 |
COVANCE LABORATORIES LTD
Organization address
address: OTLEY ROAD contact info |
UK (HARROGATE) | participant | 236˙576.34 |
| 10 |
ASTRAZENECA AB
Organization address
address: Vastra Maelarhamnen contact info |
SE (SODERTAELJE) | participant | 226˙936.70 |
| 11 |
CELLECTIS SA
Organization address
address: RUE JEAN ANTOINE DE BAIF 12 contact info |
FR (PARIS) | participant | 210˙353.20 |
| 12 |
Department of Health
Organization address
address: Quarry House, Quarry Hill contact info |
UK (Leeds) | participant | 167˙404.69 |
| 13 |
INSERM - TRANSFERT SA
Organization address
address: Rue Watt 7 contact info |
FR (PARIS) | participant | 160˙800.00 |
| 14 |
AVANTEA srl
Organization address
address: via Cabrini 12 contact info |
IT (Cremona) | participant | 155˙570.00 |
| 15 |
HEALTH PROTECTION AGENCY HPA
Organization address
address: Central Office - 7th Floor, Holborn Gate - High Holborn 330 contact info |
UK (LONDON) | participant | 119˙454.18 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'In the development of products for use by humans it is vital to identify compounds with toxic properties at an early stage of their development, to avoid spending time and resource on unsuitable and potentially unsafe candidate products. Human pluripotent stem cell lines offer a unique opportunity to develop a wide variety of human cell-based test systems because they may be expanded indefinitely and triggered to differentiate into any cell type. SCR&Tox aims at making use of these two attributes to provide in vitro assays for predicting toxicity of pharmaceutical compounds and cosmetic ingredients. The consortium has been designed to address all issues related with biological and technological resources to meet that goal. In order to demonstrate the value of pluripotent stem cells for toxicology, the consortium will focus on four complementary aspects: Relevance –i.e. establishing and maintaining discrete cell phenotypes over long-term cultures; providing large versatility to adapt to assays of specific pathways. Efficiency –for i) automated cell production and differentiation, ii) cell engineering for differentiation and selection iii) multi-parametric toxicology using functional genomic, proteomic and bioelectronics. Extension –i.e. i) scalability through production of cells and technologies for industrial-scale assays, and ii) diversity of phenotypes (5 different tissues), and of genotypes (over 30 different donors). Normalization –validation and demonstration of reproducibility and robustness of cell-based assays on industrial-scale platforms, to allow for secondary development in the pharmaceutical and cosmetic industry. SCR&Tox will be intricately associated to other consortia of the “Alternative Testing” call, sharing biological, technological and methodological resources. Proof of concept of the proposed pluripotent stem cell-based assays for toxicology will be provided on the basis of toxicity pathways and test compounds identified by other consortia.'
Altri progetti dello stesso programma (FP7-HEALTH)
CARTARDIS (2013)
Identification and validation of novel pharmaceutical drug targets for cardiovascular disease
Read MoreHEAR-EU (2012)
High-resolution image-based computational inner ear modelling for surgical planning of cochlear implantation
Read MoreMITOCARE (2011)
Treatment of reperfusion injury using a mitochondrial targeted approach: towards a better understanding of the disease
Read More